NASDAQ:ATHE

Alterity Therapeutics Stock Insider Trading

etoro logo Buy ATHE
*Your capital is at risk
$4.96
+0.0300 (+0.609%)
At Close: Jun 23, 2026

Alterity Therapeutics Stock Insider Power

Based on the 16 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 416.57M and sold 0 ATHE shares in the last 16 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 16 transactions)
100.00
Buy 416.57M shares
Sell 0 shares
100% Buy Activity
Weak Positive Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Apr 17, 2026
Buy
Common Stock
J-Other
Cunningham Ann Michelle
Director 0
Value: $0
Apr 15, 2026
Buy
Ordinary shares
Stamler David Allen
Chief Executive Officer
CEO / President 0
Value: $0
Apr 15, 2026
Buy
American Depositary Shares (1:600 ordinary shares)
Stamler David Allen
Chief Executive Officer
CEO / President 0
Value: $0
Apr 15, 2026
Buy
Unlisted option exp 21 March 2029
Stamler David Allen
Chief Executive Officer
CEO / President 40 000 200
Value: $120.0K
Apr 15, 2026
Buy
Unlisted option exp 8 August 2030
Stamler David Allen
Chief Executive Officer
CEO / President 290 400 000
Value: $2.50M
Apr 15, 2026
Buy
Listed option exp 31 August 2026
Stamler David Allen
Chief Executive Officer
CEO / President 2 380 952
Value: $23.8K
Apr 15, 2026
Buy
Listed option exp 26 Feb 2027
Stamler David Allen
Chief Executive Officer
CEO / President 1 515 152
Value: $42.4K
Apr 10, 2026
Buy
Ordinary shares
Gozlan Lawrence Bernard
Director
Director 0
Value: $0
Apr 10, 2026
Buy
Listed option exp 26 Feb 2027
Gozlan Lawrence Bernard
Director
Director 1 515 152
Value: $42.4K
Apr 10, 2026
Buy
Unlisted option exp 30 Dec 2027
Gozlan Lawrence Bernard
Director
Director 50 000 000
Value: $500.0K
Apr 10, 2026
Buy
Common Stock
J-Other
Babarczy Julian Michael
Director 0
Value: $0
Apr 10, 2026
Buy
Ordinary shares
Marks Peter Ashley
Director
Director 0
Value: $0
Apr 10, 2026
Buy
Listed option exp 26 Feb 2027
Marks Peter Ashley
Director
Director 606 061
Value: $17.0K
Apr 10, 2026
Buy
Unlisted option exp 30 Dec 2027
Marks Peter Ashley
Director
Director 30 000 000
Value: $300.0K
Apr 10, 2026
Buy
Listed option exp 26 Feb 2027
Macnish Niven Abby Sarah
Chief Financial Officer
C-Suite Officer 151 510
Value: $4K
Apr 09, 2026
Buy
Ordinary shares
Macnish Niven Abby Sarah
Chief Financial Officer
C-Suite Officer 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ALTERITY THERAPEUTICS LIMITED
Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company ...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
20.46% Jun 12
DHI
$146.71
6.39% Jun 10
E
ETD
$20.67
4.79% Jun 05
EAT
$140.46
16.94% Jun 05
OSW
$24.00
17.08% Jun 04

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE